AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01154348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, S-707106 plus metformin
Description: Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily
Study NCT01154348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin, placebo plus metformin
Description: Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily
Study NCT03359668 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Use of IV contrast during head and neck CT
Description: Use of IV contrast during head and neck CT
Study NCT03359668 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Use of IV contrast during head and neck CT
Description: Use of IV contrast during head and neck CT
Study NCT04097262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own-Price Elasticity
Description: The price of fruit will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
Study NCT04097262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-Price Elasticity
Description: The price of fruit will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
Study NCT03592667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg, one per day before breakfast during 12 weeks.
Study NCT03592667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: One per day before breakfast during 12 weeks.
Study NCT01098760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment
Description: Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks
Study NCT02857946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prevaglip (linagliptin)
Description: 1 tablet contains 5 mg linagliptin
Study NCT02857946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trajenta (linagliptin)
Description: 1 tablet contains 5 mg linagliptin
Study NCT02269514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette #3
Description: VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
Study NCT02269514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leading U.S. Nicotine Gum
Description: 4 mg nicotine polacrilex gum
Study NCT03181269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention education
Description: An education package that includes an enhanced emphasis on maternal-infant skin-to-skin contact and a detailed activity log for recording early post-partum care practices that includes specific skin-to-skin contact time and frequency goals.
Study NCT04606537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg itraconazole, given orally as 20 mL × 10-mg/mL solution BID on Day 15, followed by QD dosing on Days 16 through 23, inclusive.
Study NCT04606537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg rifampin, given orally as 2 × 300-mg capsules QD on Days 15 through 25, inclusive.
Study NCT03181269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Education
Description: An education package that includes a basic emphasis on maternal-infant skin-to-skin contact, as well as other general post-partum care practices and a general early post-partum care practices log without specific skin-to-skin contact goals.
Study NCT04606537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: 0.5 mg KBP-5074, given orally as 1 × 0.5-mg tablet on Days 1 and 19 or Days 1 and 21
Study NCT03848598 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of local tendon deformation
Description: Ultrasound-based speckle tracking to evaluate the local tendon tissue displacement during isometric exercise.
Study NCT04182854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemid hydrochlorothiazide
Description: furosemide 100mg for one month;furosemide 200mg for one month;furosemide 100mg and hydrochlorothiazide 25mg for one month;
Study NCT02603822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12C mannitol
Description: 12C mannitol 100 mg
Study NCT02603822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
Study NCT02603822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 13C mannitol
Description: 13C mannitol 100 mg
Study NCT02603822 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: lactulose 1 g
Study NCT01538901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
Study NCT01538901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod 5% cream
Description: 250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
Study NCT00234221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strengths Based Case Management
Study NCT00234221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy
Study NCT00234221 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Informational Feedback
Study NCT04581772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Multiple oral doses
Study NCT04581772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose
Study NCT04581772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Single oral dose
Study NCT02865499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acarbose
Description: acarbose treatment with meals
Study NCT04024540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric dietary restriction
Description: Very low caloric diet
Study NCT01370681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : HKB0701 and SLM0807, Period II : CJ30001
Study NCT01370681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period I : CJ30001, Period II : HKB0701 and SLM0807
Study NCT03757143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine-Alcohol
Description: Povidone-Iodine-Alcohol will be used to disinfect the skin
Study NCT03757143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine-Alcohol
Description: Povidone-Iodine-Alcohol will be used to disinfect the skin
Study NCT03757143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-Alcohol
Description: Chlorhexidine-Alcohol will be used to disinfect the skin
Study NCT03757143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insyte Autoguard BC Winged
Description: Pose of Insyte Autoguard BC Winged
Study NCT03757143 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insyte Autoguard BC Winged
Description: Pose of Insyte Autoguard BC Winged
Study NCT03757143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes
Description: Pose of Nexiva single port catheter
Study NCT01137552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 780
Description: AMG 780 will be administered by IV infusion every 2 weeks
Study NCT04024540 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isocaloric dietary restriction
Description: Very low caloric diet
Study NCT04024540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Laparoscopic vertical sleeve gastrectomy
Study NCT03123835 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic Intervention
Description: After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
Study NCT02262546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole extended-release (ER) tablets
Study NCT02262546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole immediate-release (IR) tablets
Study NCT02262546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT02262546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pramipexole Placebo
Study NCT02262546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Placebo
Study NCT00167830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Biweekly meetings with a behavior specialist to review subject's progress with the protocol and explore challenges subject is facing in adopting healthy lifestyle behaviors.
Study NCT00167830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength and Cardiovascular Conditioning
Description: Subjects take part in an exercise program to include 30 minutes of cardiorespiratory exercise at 70% maximum heart rate, and 30 minutes of strength training on Nautilus machines.
Study NCT00167830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food selection and portion control
Description: Subjects meet on a biweekly basis with a registered dietitian who presents educational information about healthy food selection and portion control.
Study NCT00838799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGH-896
Description: 45 mg TID, capsules, 14 weeks.
Study NCT00838799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGH-896
Description: 30 mg TID, capsules, 14 weeks.
Study NCT00838799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGH-896
Description: 15 mg TID, capsules, 14 weeks.
Study NCT00838799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: 100 mg, TID, capsules, 14 weeks.
Study NCT00838799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: TID, capsules, 14 weeks.
Study NCT00370721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT04446897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: autologous mesenchymal stem cells
Study NCT04446897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment according to clinical protocols
Study NCT00876655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 di-sodium phosphate salt
Description: One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
Study NCT00876655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 free acid phosphate
Description: One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)
Study NCT03961958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol reduction
Description: Reduction of propofol target concentration
Study NCT01745224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revlite Q switched Nd:YAG
Description: Revlite Q switched Nd:YAG 1064nm
Study NCT01745224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trivantage Q switched Nd: YAG
Description: Trivantage Q switched Nd: YAG 1064nm
Study NCT04446897 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: standard treatment according to clinical protocols
Study NCT02536014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine infusion (0.3㎍/kg/hr) from anesthetic induction to the end of pneumoperitoneum
Study NCT02536014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline infusion during the same time period
Study NCT03677011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Andrositol® Test
Description: The intervention consists in the addiction of myo-inositol directly to the semen identifying the quality of sperm prior ICSI procedure
Study NCT04840277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote hearing aid adjustment
Description: The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
Study NCT01396317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
Study NCT03230110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: WP200U home sleep study device
Description: WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
Study NCT00287183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04494700 (TTP488)
Description: 60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
Study NCT00287183 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02078947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Exercise
Study NCT03303573 — intervention group
Intervention type: DRUG
Intervention: recombinant human erythropoietin
Description: Subcutaneous rhEPO injection
Study NCT01683266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (Insulin glargine new formulation)
Study NCT01683266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (Insulin glargine)
Study NCT00679029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00679029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00679029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00679029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00679029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00679029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00679029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given subcutaneously
Study NCT02357160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artwork
Description: Prints by local artists that are hung on the walls of patient rooms.
Study NCT02357160 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Artwork
Description: Prints by local artists that are hung on the walls of patient rooms.
Study NCT02357160 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Artwork
Description: Prints by local artists that are hung on the walls of patient rooms.
Study NCT04379531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-dose Chest CT
Description: Patients referred by the primary care physician with suspected pneumonia.
Study NCT04379531 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose Chest CT
Description: Patients referred by the primary care physician with suspected pneumonia.
Study NCT03118362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Description: Parenteral administration of Plasmalyte initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days.
Study NCT03118362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer lactate
Description: Parenteral administration of Ringer lactate initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days.
Study NCT02949843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Receive other treatment
Study NCT02949843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Receive other treatment
Study NCT03156465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid L24
Description: Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
Study NCT02676193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effect of Packaging on Smoking Perceptions and Behavior
Description: The intervention is the use of the assigned pack design.
Study NCT04447768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Cycle 1, Day 1- 100 mg~Cycle 1, Day 2 - 900 mg~Cycle 1, Day 8 - 1000 mg~Cycle 1, Day 15 -1000 mg~Cycle 2, Day 1 to Cycle 6, Day 1- 1000 mg
Study NCT04447768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Cycle 1, Day 22 to 28 -20 mg daily~Cycle 2, Day 1 to Day 7 -50 mg daily~Cycle 2, Day 8 to Day 14- 100 mg daily~Cycle 2, Day 15 to Day 21- 200 mg daily~Cycle 2, Day 22 to Day 28 - 400 mg daily~Cycle 3, Day 1 to end of Cycle 12-24 - 400 mg daily
Study NCT01381419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Single dose.
Study NCT01381419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
Study NCT01381419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
Study NCT04109066 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified Dose on Specified days
Study NCT04109066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel (PTX)
Description: Specified dose on Specified days
Study NCT04109066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel (PTX)
Description: Specified dose on Specified days
Study NCT04109066 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nivolumab placebo
Description: Specified dose on Specified days
Study NCT04109066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anthracycline
Description: Specified dose on Specified days
Study NCT04109066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anthracycline
Description: Specified dose on Specified days
Study NCT04109066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Specified dose on Specified days
Study NCT04109066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclophosphamide
Description: Specified dose on Specified days
Study NCT04109066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: Variable endocrine therapy of investigators choice
Study NCT04109066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endocrine Therapy
Description: Variable endocrine therapy of investigators choice
Study NCT04109066 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery for breast cancer